Key result
Brief PROMIS-Anx tool correlates moderately with standard SCARED screening in pediatric heart disease.
Why the study?
Anxiety disorders are common in pediatric heart disease, but the standard SCARED screening tool is too lengthy to complete in a busy pediatric cardiology clinic.
Does the PROMIS-Anx screening tool demonstrate concurrent validity relative to the SCARED tool for identifying anxiety in children with pediatric heart disease?
Observational
Does the PROMIS-Anx screening tool demonstrate concurrent validity relative to the SCARED tool for identifying anxiety in children with pediatric heart disease?
Effect estimate: = 0.58
p-value: p=< 0.001
The brief PROMIS-Anx screening tool is a valid alternative to the longer SCARED tool for identifying anxiety in pediatric cardiology clinics.
Moderate correlation supports PROMIS-Anx as shorter anxiety screen in pediatric heart disease; leaves open prospective validation before adoption.
BACKGROUND: Anxiety disorders are common in pediatric heart disease (PHD), including congenital, arrhythmic, and acquired heart disease. The standard screening tool, Screen for Child Anxiety Related Emotional Disorders (SCARED), is too lengthy to complete in a busy pediatric cardiology clinic. OBJECTIVES: This study assessed the concurrent validity of a briefer tool, Pediatric-Reported Outcomes Measurement Information System Pediatric Anxiety (PROMIS-Anx), relative to SCARED in children with PHD. METHODS: ), and a cut point was developed for PROMIS-Anx in children and their caregivers using Youden index. RESULTS: = 0.58, P < 0.001), both reaching statistical significance. A PROMIS-Anx score of >30 was identified as a threshold for significant anxiety symptoms based on SCARED. CONCLUSIONS: PROMIS-Anx scores correlate with SCARED across the range of scores, particularly when completed by the child. Routine screening for anxiety in cardiology clinic, with a brief tool such as PROMIS-Anx, can promote earlier identification and treatment of anxiety in children with PHD.
No takes yet. Share an insight, caveat, or question.
Ahmad et al. (2026) conducted an observational in Pediatric heart disease (PHD). PROMIS-Anx vs. SCARED was evaluated on Concurrent validity of PROMIS-Anx relative to SCARED (= 0.58, p=< 0.001). The brief PROMIS-Anx screening tool significantly correlated with the standard SCARED tool (= 0.58, P < 0.001) in children with pediatric heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: